Agile therapeutics inc (AGRX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Operating expenses:
Research and development

3,164

2,837

2,361

1,779

2,881

1,855

1,549

2,413

3,960

2,734

3,175

3,798

4,721

5,514

4,911

5,577

4,927

6,914

7,162

6,168

5,378

4,977

4,602

2,390

1,394

2,397

2,425

General and administrative

4,453

3,268

2,138

1,768

1,826

1,568

1,767

2,318

3,086

3,254

3,526

3,198

2,405

2,295

2,180

2,264

2,053

2,252

1,803

1,813

1,599

1,546

1,446

1,103

1,053

923

823

Charges

-

-

-

-

-

-

299

416

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

7,617

6,105

4,499

3,547

4,707

3,727

3,615

5,147

7,046

5,988

6,701

6,996

7,126

7,809

7,091

7,841

6,980

9,166

8,965

7,981

6,977

6,523

6,048

3,494

2,447

3,321

3,249

Loss from operations

-7,617

-6,105

-4,499

-3,547

-4,707

-3,727

-3,615

-5,147

-7,046

-5,988

-6,701

-6,996

-7,126

-7,809

-7,091

-7,841

-6,980

-9,166

-8,965

-7,981

-6,977

-6,523

-6,048

-3,494

-2,447

-3,321

-3,249

Other income (expense)
Interest income

132

84

67

63

38

77

91

101

97

96

78

61

47

34

33

33

17

2

1

1

1

1

1

0

0

0

0

Interest expense

398

-

-

-

-

160

268

320

368

409

459

504

546

566

784

548

548

554

551

547

425

392

392

403

378

378

378

Change in fair value of warrants

-

-

-

-

-

-

0

-22

-7

-

20

7

-109

-65

-38

62

-193

154

-104

-41

101

-69

-86

-179

-12

-8

-7

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-1,036

-

-

-

-

-

-

Total other income (expense), net

-266

84

67

63

38

-83

-177

-197

-264

-252

-401

-450

-390

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before benefit from income taxes

-7,883

-6,021

-4,432

-3,484

-4,669

-3,810

-3,792

-5,344

-7,310

-6,240

-7,102

-7,446

-7,516

-8,276

-7,804

-8,418

-7,318

-9,872

-9,411

-8,486

-8,538

-

-6,353

-3,718

-

-

-

Loss before benefit from income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,813

-3,690

-3,619

Benefit from income taxes

-

-

-

-

-

0

0

0

-477

-

-

-

-

-

-

-

-

-

-

-

-

-0

0

0

-3,652

-

-

Net loss

-7,883

-6,021

-4,432

-3,484

-4,669

-3,810

-3,792

-5,344

-6,833

-6,240

-7,102

-7,446

-7,516

-

-

-

-

-

-

-

-

-

-

-

839

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,804

-8,418

-7,318

-

-9,411

-8,486

-8,538

-

-6,353

-3,718

-

-3,690

-3,619

Net loss per share (basic and diluted) (in dollars per share)

-0.10

-0.09

-0.08

-0.08

-0.13

-0.11

-0.11

-0.16

-0.20

-0.17

-0.22

-0.26

-0.26

-0.19

-0.27

-0.29

-0.27

-0.18

-0.42

-0.38

-0.40

-

-0.34

-0.46

-

-71.67

-70.29

Weighted-average common shares (basic and diluted) (in shares)

76,652

63,035

53,609

43,776

37,308

34,379

34,377

34,277

34,229

34,254

31,937

28,802

28,769

28,768

28,754

28,744

26,826

22,310

22,272

22,202

21,282

-

18,592

8,000

-

51

51

Net (loss) income per share (basic)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

-

-

Net (loss) income per share (diluted)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.01

-

-

Weighted-average shares outstanding (basic)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

106

-

-

Weighted-average shares outstanding (diluted)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

822

-

-